logo
Share SHARE
FONT-SIZE Plus   Neg

Onyx's Kyprolis Gets FDA Approval For Multiple Myeloma, Shares Up 5%

US Food and Drug Administration granted accelerated approval for Onyx Pharmaceuticals Inc.'s (ONXX) Kyprolis for treatment of patients with multiple myeloma who have received at least two prior therapies. Following the news, shares of Onyx Pharmaceuticals rose over five percent on the Nasdaq.

Kyprolis, whose chemical name is Carfilzomib, is a next-generation proteasome inhibitor, belonging to the same class as Takeda Pharmaceutical Co.'s multiple myeloma treatment Velcade.

The FDA approved Kyprolis for treatment of patients who failed to successfully treat their blood cancer with at least two medicines, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

The indication for Kyprolis is based on response rate. Currently, no data are available for Kyprolis that demonstrate an improvement in progression-free survival or overall survival.

Multiple myeloma is a type of blood cancer, and an estimated 200,000 people worldwide are living with this disease. In the U.S, about 50,000 people are affected by multiple myeloma, and 20,000 new cases are diagnosed each year. Onyx sees over $2 billion global sales opportunity in multiple myeloma.

Chief Exective Anthony Coles said, "Today's approval is a significant milestone for Onyx and, most importantly, for patients with advanced myeloma who have few treatment options available to them."

The approval was based on the results of the Phase 2b 003-A1 study, a single-arm, multicenter clinical trial that enrolled 266 patients with multiple myeloma. The overall response rate was 22.9 percent and median response duration was 7.8 months.

Onyx shares is currently trading at $71.95, up $3.55 or 5.19%, on a volume of 1.7 million.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Alphabet Inc. (GOOG, GOOGL), the parent company of Google, Thursday reported an increase in profit for the first quarter, driven largely revenue growth in search and advertising. Alphabet's first-quarter profit rose to $5.43 billion or $7.73 per share from $4.21 billion or $6.02 per share last year. On... A passenger was booted from a Delta Air Lines flight after an emergency run to the bathroom while the plane was delayed for almost two hours on the tarmac, according to media reports. Kima Hamilton, 39, reportedly said that he needed to use the restroom while the plane was on the tarmac in Atlanta en route to Milwaukee on April 18. McDonald's is going to discontinue a popular item that has been on the menu for decades - the Hi-C Orange Lavaburst - from May 1, according to a memo posted on Reditt. With customers having only a few more days to get their hands on the iconic, popular beverage before its gone forever, McDonald's is already facing a backlash for its decision.
comments powered by Disqus
Follow RTT